GGrantIndex
← Search

A RANDOMIZED PHASE 2 TRIAL EVALUATING THE NOVEL PI3KD INHIBITOR ROGINOLISIB WITH VENETOCLAX/RITUXIMAB FOR THE TREATMENT OF RELAPSED CLL PATIENTS

$4,753,460FY2024Defense Health AgencyDOD

Dana-Farber Cancer Institute, Inc.

Investigators

View source on USAspending →
A RANDOMIZED PHASE 2 TRIAL EVALUATING THE NOVEL PI3KD INHIBITOR ROGINOLISIB WITH VENETOCLAX/RITUXIMAB FOR THE TREATMENT OF RELAPSED CLL PATIENTS · GrantIndex